Ultragenyx (NASDAQ: RARE) granted 65,886 restricted stock units (RSUs) of its common stock to 39 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan. The RSUs, granted on July 16, 2026, vest over four years at 25% per year, subject to continued employment.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – RARE
-0.04%
-0.04%Session close to close
In the Jul 27 session, RARE declined 0.04%, reflecting a mild negative market reaction.
RARE's recent news record included reactions from -3.35% to 5.79%, adding variability context to thi...
Analysis
RARE's recent news record included reactions from -3.35% to 5.79%, adding variability context to this inducement announcement. The platform also records net selling by insiders; additional filings and market context remain relevant.
Key Figures
Restricted Stock Units:65,886 RSUsRecipients:39 officersGrant Date:July 16, 2026+2 more
5 metrics
Restricted Stock Units65,886 RSUsGranted to newly hired employees
Scheduled executive fireside appearance at Bank of America's healthcare conference
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
RARE's prior neutral news announcements produced mixed 24-hour reactions, ranging from -3.35% to 5.79%, with no consistent directional pattern.
Key Terms
restricted stock units, nasdaq listing rule 5635(c)(4), inducement grant
3 terms
restricted stock unitsfinancial
"reported the grant of 65,886 restricted stock units of the company’s common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4)regulatory
"in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement grantfinancial
"Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"
An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.
NOVATO, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 65,886 restricted stock units of the company’s common stock to 39 newly hired non-executive officers of the company.The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
About Ultragenyx Pharmaceutical Inc. Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx Investors & Media Joshua Higa (415) 475-6370
FAQ
What inducement equity grant did Ultragenyx (RARE) announce on July 24, 2026?
Ultragenyx announced an equity inducement grant of 65,886 restricted stock units (RSUs) to 39 newly hired non-executive officers. According to Ultragenyx, the RSUs were granted under its Employment Inducement Plan with a grant date of July 16, 2026, as a material employment inducement.
How many employees are included in the July 2026 Ultragenyx (RARE) inducement RSU grant?
Ultragenyx granted inducement RSUs to 39 newly hired non-executive officers. According to Ultragenyx, these awards were approved by the board’s compensation committee and are intended as a material inducement for the new employees to enter into employment with the company under Nasdaq Listing Rule 5635(c)(4).
What is the vesting schedule for the 65,886 Ultragenyx (RARE) inducement RSUs granted in July 2026?
The 65,886 inducement RSUs vest over four years at 25% per year. According to Ultragenyx, 25% of the underlying shares vest on each anniversary of the July 16, 2026 grant date, contingent on the employee’s continuous employment on each vesting date.
Under which plan were the July 16, 2026 Ultragenyx (RARE) inducement RSUs granted?
The July 16, 2026 inducement RSUs were granted under the Ultragenyx Employment Inducement Plan. According to Ultragenyx, these awards were approved by the compensation committee and structured to comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement to new employees entering employment.
How does Nasdaq Listing Rule 5635(c)(4) relate to Ultragenyx’s July 2026 RSU grant (RARE)?
The July 2026 RSU grant was made in reliance on Nasdaq Listing Rule 5635(c)(4), which permits inducement equity awards. According to Ultragenyx, the RSUs were granted as a material inducement for 39 newly hired non-executive officers to enter into employment with the company.
